Cardiovascular | Eannatto Delta Gold

Cardiovascular Study

Cardiovascular diseases (CVDs) are the number 1 cause of death globally. An estimated 17.9 million people died from cardiovascular diseases in 2016 representing 31% of all global deaths in 2016. Out of these, 85% were due to heart attack and stroke. According to the American Heart Association, a new clinical study has suggested that Tocotrienols from Annatto may enhance cardiovascular benefits. A Canadian company, Eannatto has successfully harvested Annatto for Tocotrienols to deliver it to every corner of the world to provide maximum health benefits.

Why Tocotrienol?

  • Cholesterol reduction is a significant feature of Tocotrienols by suppression of HMGR (3-hydroxy3methyl-glutaryl-CoA reductase) the enzyme/protein responsible for the body’s cholesterol production.
  • Cytokines associated with cardiovascular diseases were down-regulated by Tocotrienols according to the study done at the University of Missouri – Kansas City.
  • MicroRNAs which are usually down-regulated in hyper-cholesterolemic individuals are up-regulated by Tocotrienol treatment as per the study.
  • Cellular adhesion molecule expression has been observed to be reduced by Tocotrienols.
  • Monocytic cell adherence has also been found to be reduced by Tocotrienol in multiple kinds of research.
  • ‘Velcro effect”, a process which initiates plaque formation in arterial walls has also been observed to be reduced by Tocotrienol.
  • Lipid peroxides in blood vessels and blood pressure have been observed to be lowered by Tocotrienols which improves total anti-oxidant status thus preventing hypertension.
  • Carotid Arteriosclerosis has been observed to be reduced by Tocotrienol in several studies.
  • Anti-inflammation are characteristic properties of Tocotrienols.

Dosage

In several studies, 100 mg/day of Tocotrienols was found effective for cholesterol and triglyceride reduction. However, the dosage varies for different CVDs.

Why Tocotrienol and not Tocopherol?

  • Ineffective Tocopherol: Large clinical studies on alpha-tocopherol have shown it to be ineffective and possibly harmful. Also, Tocopherols do not have the cholesterol-lowering ability which Tocotrienols do.
  • The inability of Tocopherol to regulate Cholesterol Synthesis: While Tocopherol has antioxidant value, they lack the ability to regulate cholesterol synthesis.
  • Structure of Tocotrienol: Tocotrienol has a smaller structure and less molecular weight which helps it to move freely through the cell membranes to cover larger areas for added protection.
  • Tocopherol, the enemy of Tocotrienol: Alpha-tocopherol has been observed to attenuate or interfere with the cholesterol-lowering function of Tocotrienols. Preparations effective in cholesterol-lowering action consist of 15% or less of alpha-tocopherol and 60% or more gamma and delta Tocotrienols while ineffective preparations consist of 20% or more alpha-tocopherol and 45% or less of gamma and delta-tocotrienols.
  • Absorption: As compared to Tocopherols, Tocotrienols absorb better in the body and Tocopherols have been observed to prevent absorption of Tocotrienols.

References

Add to cart